EADV 2025: Full Congress Recap

The European Academy of Dermatology and Venereology Congress is complete! Check out our full conference recap below. To stay informed with the latest insights from across the globe, subscribe to receive our eNewsletters and follow Dermatology Times on LinkedIn, Facebook, and X.

POLL: Are You Attending the EADV Congress 2025?

Join Dermatology Times at the EADV Congress 2025 for expert insights and live updates from Paris, France.

Zasocitinib Shows Early DLQI Gains in Patients with Psoriasis

Benefits of zasocitinib on quality of life were observed as early as week 4 and sustained through week 12.

Bimekizumab Sustains PASI 0 in Nearly Half of Patients to Year 4

By blocking 2 key inflammation signals, research found bimekizumab may help keep both skin and joints healthier over time.

Povorcitinib Shows Sustained Efficacy in HS at 24 Weeks

STOP-HS1 and STOP-HS2 phase 3 trials showed nearly 60% of patients achieving HiSCR50 by week 24.

Three-Year Data Reinforce Long-Term Efficacy and Safety of Bimekizumab in Hidradenitis Suppurativa

UCB presented new long-term data demonstrating bimekizumab’s durable efficacy and a consistent safety profile over extended treatment.

Sanofi Announces Positive Phase 2a Results for Brivekimig in HS

Sanofi's brivekimig shows promising phase 2a results for hidradenitis suppurativa, offering hope for effective treatment options.

Celldex Reports Strong Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria Across IgE Subgroups

According to a poster, barzolvolimab achieved comparable improvements in weekly urticaria activity scores across lgE subgroups.

Global Study Links Atopic Eczema to Increased Risk of Suicidal Ideation

A new study links atopic dermatitis to increased suicidal ideation, highlighting the condition's severe psychological impact.

Oral IL-23 Blocker Shows Durable Psoriasis Control at 1 Year

The trial confirmed that icotrokinra’s efficacy is consistent with injectable IL-23 inhibitors while offering an oral option.

Icotrokinra Outperforms Deucravacitinib in Psoriasis Phase 3 Trials

Phase 3 ICONIC-ADVANCE data showed icotrokinra outperformed deucravacitinib in moderate to severe psoriasis.

Ruxolitinib Cream Shows Promise in Prurigo Nodularis at EADV 2025

A meaningful difference in WI-NRS scores was observed as early as day 3 of treatment with ruxolitinib cream.

A Paradigm Shift in Psoriasis Care: Almirall's POSITIVE Study and the Focus on Patient Well-Being

Almirall's POSITIVE study, presented at EADV 2025, prioritizes patient well-being, showcasing the holistic impact of advanced treatments.

Oral TNFR1 Inhibitor Balinatumab Shows Promise in Psoriasis

Balinatumab was generally well tolerated, with common adverse events such as nausea and arthralgia also observed in placebo groups.

OX40 Inhibition Delivers Significant Response in Treatment-Experienced AD

The ROCKET-SHUTTLE trial demonstrates that rocatinlimab, a T-cell rebalancing therapy, significantly improves the signs and symptoms of moderate to severe AD in adults when used with topical therapies.

Galvokimig Achieves High EASI Scores in Pilot Study

Presented at EADV, galvokimig showed promising early results in treating moderate to severe atopic dermatitis, targeting multiple inflammatory pathways for effective relief.

LEO Pharma Presents Late-Breaking Results on Temtokibart for Atopic Dermatitis at EADV

LEO Pharma unveils promising phase 2b trial results for temtokibart, showcasing significant improvements in atopic dermatitis at EADV Congress 2025.

Study Finds Psoriasis Linked to Increased Risk of Age-Related Macular Degeneration

Findings from a large retrospective study presented at EADV 2025 suggest psoriasis significantly increases the risk of both wet and dry age-related macular degeneration.

Peter Lio, MD, at EADV 2025: Rethinking the Atopic Dermatitis Journey

Major unmet needs in pediatric AD include rapid itch relief, access, affordability, and better options for sensitive skin.

Ascletis Presents Positive Phase 3 Data for Denifanstat in Moderate to Severe Acne

Denifanstat shows promising results in treating moderate to severe acne vulgaris, achieving significant efficacy and safety at the EADV Congress 2025.

Guttman-Yassky Showcases 2 Paths to Long-Term AD Control at EADV 2025

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader

The oral degrader produced biomarker reductions consistent with or superior to dupilumab.

Rocatinlimab Maintains Safety Profile in 24-Week AD Study

Together with earlier trials presented at EADV, these findings support OX40 receptor inhibition as a promising therapeutic approach for AD.

DELTA TEEN Trial Demonstrates Superiority of Delgocitinib Cream in Adolescents With Chronic Hand Eczema

Late-breaking EADV 2025 presentations highlighted positive efficacy outcomes in the adolescent population and pooled safety data across 5 phase 2b and phase 3 trials of delgocitinib cream.

Bunick Discusses Dual-Target Biologic at EADV 2025

Galvokamig, a biologic targeting IL-13 and IL-17A/F, demonstrated significant benefits in moderate to severe atopic dermatitis.

APG777 Trial Demonstrates Efficacy, Safety in AD

Treatment with APG777 led to a significant 71.0% reduction in EASI scores from baseline to week 16, compared to a 33.8% reduction with placebo.